如何在撒哈拉以南非洲治疗儿童、青少年和年轻成人伯基特淋巴瘤
伯基特淋巴瘤是撒哈拉以南非洲最常见的儿童肿瘤,也常见于青少年和年轻成人,常与HIV相关。本文基于该地区证据,综述诊断、预化疗和确定性治疗策略,讨论含蒽环类和/或大剂量全身甲氨蝶呤方案的安全性、可行性和结局,并概述研究优先方向。
要点
- 撒哈拉以南非洲伯基特淋巴瘤治疗需基于区域证据选择方案
- 高强度细胞毒治疗通常不可行,低强度持续输注方法不切实际
- 含蒽环类和/或大剂量全身甲氨蝶呤方案相对安全性、可行性和结局需讨论
核心结论
- 基于区域证据综述了撒哈拉以南非洲伯基特淋巴瘤的诊断、预化疗和确定性治疗策略,并讨论了含蒽环类和/或大剂量全身甲氨蝶呤方案的相对安全性、可行性和结局。
- 需要持续致力于渐进式改进和创新,通过国际合作改变撒哈拉以南非洲伯基特淋巴瘤的治疗和结局。
研究设计与样本
- 本文为综述,基于撒哈拉以南非洲区域的证据。
主要发现
- 伯基特淋巴瘤是撒哈拉以南非洲最常见的儿童肿瘤,也常发生于青少年和年轻成人,常与HIV相关。
- 在资源丰富地区使用的高强度细胞毒治疗通常不可行,低强度持续输注方法不切实际。
- 与历史极低强度方案相比,含蒽环类和/或大剂量全身甲氨蝶呤方案的相对安全性、可行性和结局被讨论。
关键数值与推荐
- 原文未报告具体数值标准或推荐等级。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Burkitt lymphoma (BL) is the most common pediatric cancer in sub-Saharan Africa (SSA), and also occurs frequently among adolescents and young adults (AYAs), often associated with HIV. Treating BL in SSA poses particular challenges. Although highly effective, high-intensity cytotoxic treatments used in resource-rich settings are usually not feasible, and lower-intensity continuous infusion approaches are impractical. In this article, based on evidence from the region, we review management strategies for SSA focused on diagnosis and use of prephase and definitive treatment. Additionally, potentially better approaches for risk stratification and individualized therapy are elaborated. Compared with historical very low-intensity approaches, the relative safety, feasibility, and outcomes of regimens incorporating anthracyclines and/or high-dose systemic methotrexate for this population are discussed, along with requirements to administer such regimens safely. Finally, research priorities for BL in SSA are outlined including novel therapies, to reduce the unacceptable gap in outcomes for patients in SSA vs high-income countries (HICs). Sustained commitment to incremental advances and innovation, as in cooperative pediatric oncology groups in HICs, is required to transform care and outcomes for BL in SSA through international collaboration.
引用
- Gopal S, Gross TG. How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa. Blood. 2018. PMID: 29769263. doi:10.1182/blood-2018-04-844472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。